Glycotope's Fully Human and Glyco-Optimized Recombinant FSH-GEX Showed Superior Activity and Excellent Tolerability in a Phase II Clinical Trial for IVF
Glycotope GmbH, a global leader in developing therapeutic antibodies targeting glycosylated epitopes on cancer cells and optimising the sugar chains (glycosylation) of biopharmaceuticals, has announced results from the Phase II clinical trial with FSH-GEX for Assisted Reproductive Technologies.
Results showed that FSH-GEX has superior activity and excellent tolerability when compared with the standard treatment Gonal-f. FSH-GEX is the first fully human glycosylated FSH (follicle-stimulating hormone), recombinantly expressed in human cells and glyco-optimized to mimic endogenous human FSH.
The Phase II, multicenter, multinational, randomised clinical trial investigated the efficacy and safety of varying doses and schedules of FSH-GEX in comparison with daily 150 IU Gonal-f in 247 women undergoing artificial insemination by intracytoplasmic sperm injection (ICSI) treatment in an agonist protocol. FSH-GEX was tested in five dose cohorts, 52.5 IU, 75 IU, 112.5 IU and 150 IU daily doses, and 150 IU given every second day, compared with the standard daily dose of 150 IU Gonal-f.
The data show that FSH-GEX, even at half the biologic dose (75 IU FSH-GEX), is at least as active as Gonal-f (150 IU) in all FSH mediated parameters and endpoints. These data confirm the superior preclinical, Phase Ia and Ib data regarding biological activity and clinical efficacy.
For example, the FSH-GEX dose of 112.5 IU, showed superiority over all FSH mediated aspects and endpoints compared with a 33% higher Gonal-f standard dose including follicular response, as well as high biochemical (57.5%) and ongoing (50.0%) pregnancy rates. Particularly important for future clinical use are the statistically significantly improved numbers of retrieved oocyte complexes (+29.5%) and high quality metaphase II oocytes (+24.5%), as well as a strong trend for more pronuclear (PN) 2 oocytes (+21%) which could be observed in this dose regimen.
Furthermore, the results at a dose regimen with 150 IU FSH-GEX applied every second day and 75 IU FSH-GEX administered on a daily basis were fully comparable, allowing for a flexible or alternative dosing regimen with the same product.
The treatment with FSH-GEX was safe and very well tolerated, whereas Gonal-f showed the highest rate of OHSS (Ovarian hyperstimulation syndrome) during the trial. No inductions of anti drug antibody (ADA) responses were observed in FSH-GEX patients.
"FSH-GEX is the first of our glyco-optimized, fully human non-antibody molecules validating our unique GlycoExpress platform and proving our commitment to delivering better, clinically superior therapies combined with commercially attractive terms," said Dr Steffen Goletz, CEO, CSO and Founder of Glycotope.
"The superior activity and improved properties of FSH-GEX, which allows for lower FSH doses and the significantly improved numbers of high quality mature oocytes that can be achieved for IVF, are seen as a key driver for best clinical performances. These results strongly indicate not only a high relevance of FSH-GEX in the tested broad patient cohort, but also yield hope for women whose ovaries are particularly hard to stimulate and who are experiencing major difficulties in becoming pregnant. We are excited about these results and anticipate starting Phase III clinical trials in 2014," he added.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance